Teva Pharmaceutical Industries (TEVA) Enterprise Value (2016 - 2025)
Teva Pharmaceutical Industries (TEVA) has disclosed Enterprise Value for 17 consecutive years, with -$3.6 billion as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 7.87% year-over-year to -$3.6 billion, compared with a TTM value of -$3.6 billion through Dec 2025, down 7.87%, and an annual FY2025 reading of -$3.6 billion, down 7.87% over the prior year.
- Enterprise Value was -$3.6 billion for Q4 2025 at Teva Pharmaceutical Industries, down from -$2.2 billion in the prior quarter.
- Across five years, Enterprise Value topped out at -$768.0 million in Q1 2021 and bottomed at -$3.6 billion in Q4 2025.
- Average Enterprise Value over 5 years is -$1.9 billion, with a median of -$1.9 billion recorded in 2022.
- The sharpest move saw Enterprise Value soared 39.68% in 2021, then crashed 95.83% in 2024.
- Year by year, Enterprise Value stood at -$1.2 billion in 2021, then crashed by 67.39% to -$2.0 billion in 2022, then dropped by 29.85% to -$2.6 billion in 2023, then dropped by 26.36% to -$3.3 billion in 2024, then decreased by 7.87% to -$3.6 billion in 2025.
- Business Quant data shows Enterprise Value for TEVA at -$3.6 billion in Q4 2025, -$2.2 billion in Q3 2025, and -$2.2 billion in Q2 2025.